- Home
- CVKD vs PRPH Comparison
CVKD vs PRPH Comparison
Compare CVKD & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- PRPH
- Stock Information
- Founded
- CVKD 2022
- PRPH 1989
- Country
- CVKD United States
- PRPH United States
- Employees
- CVKD N/A
- PRPH N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- PRPH Health Care
- Exchange
- CVKD Nasdaq
- PRPH Nasdaq
- Market Cap
- CVKD 27.0M
- PRPH 21.9M
- IPO Year
- CVKD 2023
- PRPH 1997
- Fundamental
- Price
- CVKD $11.25
- PRPH $0.28
- Analyst Decision
- CVKD Strong Buy
- PRPH
- Analyst Count
- CVKD 1
- PRPH 0
- Target Price
- CVKD $32.00
- PRPH N/A
- AVG Volume (30 Days)
- CVKD 21.9K
- PRPH 1.3M
- Earning Date
- CVKD 11-10-2025
- PRPH 11-07-2025
- Dividend Yield
- CVKD N/A
- PRPH N/A
- EPS Growth
- CVKD N/A
- PRPH N/A
- EPS
- CVKD N/A
- PRPH N/A
- Revenue
- CVKD N/A
- PRPH $5,588,000.00
- Revenue This Year
- CVKD N/A
- PRPH $221.82
- Revenue Next Year
- CVKD N/A
- PRPH N/A
- P/E Ratio
- CVKD N/A
- PRPH N/A
- Revenue Growth
- CVKD N/A
- PRPH N/A
- 52 Week Low
- CVKD $8.74
- PRPH $0.22
- 52 Week High
- CVKD $22.90
- PRPH $0.93
- Technical
- Relative Strength Index (RSI)
- CVKD 39.39
- PRPH 35.09
- Support Level
- CVKD $11.51
- PRPH $0.26
- Resistance Level
- CVKD $13.01
- PRPH $0.29
- Average True Range (ATR)
- CVKD 0.82
- PRPH 0.03
- MACD
- CVKD -0.14
- PRPH -0.01
- Stochastic Oscillator
- CVKD 21.29
- PRPH 21.42
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.